Study shows how cholesterol becomes dysregulated in brain cancer cells and reports the gene responsible for the dysregulation could be a potential target to help treat glioblastoma brain cancer.
Researchers report our gender can determine longevity and response to treatment for glioblastoma brain cancer. The study reports male survival is determined by genes that control cell division, where as female survival is often determine by genes that regulate the ability of cancer cells to migrate to different brain areas.
A new study in PNAS reports blocking the expression of MDA-9/Syntenin forces glioma stem cells to lose their ability to induce protective autophagy.
Researchers study the effect of letrozole , a drug designed for the treatment of breast cancer in postmenopausal women, on glioblastoma brain cancer.
Teriflunomide, a drug commonly used to treat multiple sclerosis, shows promise for the treatment of glioblastoma when coupled with targeted cancer therapies.
Scientists have long believed that glioblastoma multiforme, the most aggressive type of primary brain tumor, begins in glial cells that make up supportive tissue in the brain or in neural stem cells. Researchers found that the tumors can originate from other types of differentiated cells in the nervous system, including cortical neurons.
A new study reports researchers have identified a mechanism that aids the growth of glioblastoma brain cancer. By blocking the mechanism, researchers were able to halt the progression of the tumors.
Researchers have identified a biomarker that can help predict a patient's prognosis and response to therapies for glioblastoma brain cancer subtypes.
An inhibitor of the 20-HETE chemical has been used to successfully control the spread and growth of human glioblastoma and breast cancer in lab models of the diseases, researchers report.
A new brain cancer atlas maps out comprehensive, visually rich information about the anatomical and genetic bases of glioblastoma, researchers report.
Brain cancer cells resist therapy by temporarily losing gene mutations targeted by drugs, but re-amplify the mutation once the treatments have stopped, a new study reports.
Researchers discover a mechanism that may underpin the progression of glioblastoma brain cancer development.
